<DOC>
	<DOCNO>NCT00640692</DOCNO>
	<brief_summary>The purpose study determine genetic makeup gastro intestinal stomach tumor ( GISTs ) patient enrol A6181112 phase IIIb trial . Tumor sample screen mutation information use determine whether progression-free survival patient treat cancer medication sunitinib relate underlying genotype GIST .</brief_summary>
	<brief_title>Kinase Genotyping Gastro Intestinal Stomach Tumors ( GISTs ) From Patients Enrolled Pfizer A6181112 Phase IIIb Trial</brief_title>
	<detailed_description>In companion study , analyze genomic DNA GIST tumor specimens patient enrol A6181112 phase IIIb trial participate U.S. ex-U.S. medical center . Specifically , GIST sample screen mutation KIT gene exon 9 , 11 , 13 17 , PDGFRA gene exon 12 , 14 18 , determine primary kinase genotype . Subset analyse perform compare overall PFS rate observe patient primary secondary imatinib resistance . Based data previous phase I/II trial , hypothesis patient either primary secondary imatinib resistance KIT exon 9-mutant WT GIST longer PFS treat sunitinib patient exon 11-mutant GIST . We hypothesize difference observe among patient treat high-dose imatinib .</detailed_description>
	<mesh_term>Gastrointestinal Stromal Tumors</mesh_term>
	<mesh_term>Gastrointestinal Neoplasms</mesh_term>
	<mesh_term>Digestive System Neoplasms</mesh_term>
	<criteria>Patients enrol Pfizer A6181112 Patients consent analysis tumor companion study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>September 2009</verification_date>
	<keyword>Gastrointestinal stromal tumor</keyword>
	<keyword>GIST</keyword>
	<keyword>Sunitinib</keyword>
	<keyword>Imatinib</keyword>
</DOC>